Literature DB >> 19219607

Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis.

Margaret Wisłowska1, Danuta Jakubicz, Krystyna Stepień, Małgorzata Cicha.   

Abstract

Joint inflammation in rheumatoid arthritis (RA) induces local periarticular osteoporosis. Generalised bone mineral density (BMD) decrease concerns approximately 50% of rheumatic patients. Both types of bone mass depletion can issue from cytokine-induced (TNF-alpha, IL-1, IL-6) osteoclasts' activation, osteoprotegerin and its ligand's (RANKL) function disorders, patients' immobilisation and glucocorticosteroid (GCS) intake, as well as from hormonal alterations in postmenopausal women, predominate among RA individuals. The aim of the study was to compare serum concentrations of marker of bone formation--serum aminoterminal propeptide of type I collagen (PINP), and bone resorption, carboxy (C) terminal telopeptide (Ctx), bone turnover markers in RA and osteoarthritis (OA) patients and in RA groups of different disease activity, different degree of joint damage and the history of GCS intake. A total of 50 RA female patients and 50 women with knee OA were included in the study. Blood for morphology and biochemistry laboratory tests was taken. Joint X-rays to establish OA and RA diagnosis and the degree of RA progression, as well as DEXA BMD measurements were performed. PINP and Ctx concentrations were assessed. In RA patients the number of swollen and painful joints, the duration of morning stiffness, visual analogue scale values and Waaler-Rose's test activity were recorded. The Disease Activity Index (DAS 28) was counted from the appropriate formula. No differences in bone turnover markers' concentrations were noted neither between RA and OA patients nor between the RA group when compared to the one without the history of GCS use. Bone turnover markers' concentrations in RA were proportional to the number of swollen and painful joints. However, no correlation was found between the markers' concentrations and RA activity assessed by DAS 28 or by laboratory means. Ctx concentrations were higher in patients at II degree joint damage according to Larsen and Dale's than at more advanced stages. Ctx concentrations decreased with the disease duration. Serum morphogenesis and resorption markers' concentrations change in course of RA indicating the decrease in bone metabolic activity with the disease duration and progression. High RA activity and severity correlate with increased markers' levels-the resorption one. The influence of GCS on bone metabolism in RA requires further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219607     DOI: 10.1007/s00296-009-0867-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

1.  Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.

Authors:  P Garnero; E Sornay-Rendu; B Claustrat; P D Delmas
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products.

Authors:  P Garnero; P Jouvenne; N Buchs; P D Delmas; P Miossec
Journal:  Bone       Date:  1999-04       Impact factor: 4.398

Review 3.  Classification of disease: osteoarthritis.

Authors:  R D Altman
Journal:  Semin Arthritis Rheum       Date:  1991-06       Impact factor: 5.532

4.  Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis.

Authors:  R N de Nijs; J W Jacobs; J W Bijlsma; W F Lems; R F Laan; H H Houben; E J ter Borg; A M Huisman; G A Bruyn; P L van Oijen; A A Westgeest; A Algra; D M Hofman
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

5.  Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films.

Authors:  A Larsen; K Dale; M Eek
Journal:  Acta Radiol Diagn (Stockh)       Date:  1977-07

6.  Generalised bone loss in patients with early rheumatoid arthritis.

Authors:  A K Gough; J Lilley; S Eyre; R L Holder; P Emery
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

7.  Recent advances in biochemical markers of bone turnover.

Authors:  L M Demers; M Kleerekoper
Journal:  Clin Chem       Date:  1994-11       Impact factor: 8.327

Review 8.  Osteoporosis in rheumatoid arthritis.

Authors:  J Dequeker; K Maenaut; J Verwilghen; R Westhovens
Journal:  Clin Exp Rheumatol       Date:  1995 Sep-Oct       Impact factor: 4.473

9.  Spinal trabecular bone mineral content in patients with non-steroid treated rheumatoid arthritis.

Authors:  J E Compston; E O Crawley; C Evans; M M O'Sullivan
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

10.  Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis.

Authors:  A Gough; P Sambrook; J Devlin; A Huissoon; C Njeh; S Robbins; T Nguyen; P Emery
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

View more
  8 in total

Review 1.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

Review 2.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

3.  Arthritis induces early bone high turnover, structural degradation and mechanical weakness.

Authors:  Bruno Vidal; Rita Cascão; Ana Catarina Vale; Inês Cavaleiro; Maria Fátima Vaz; José Américo Almeida Brito; Helena Canhão; João Eurico Fonseca
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

4.  Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.

Authors:  Alan Sucur; Zrinka Jajic; Marinko Artukovic; Marina Ikic Matijasevic; Branimir Anic; Darja Flegar; Antonio Markotic; Tomislav Kelava; Sanja Ivcevic; Natasa Kovacic; Vedran Katavic; Danka Grcevic
Journal:  Arthritis Res Ther       Date:  2017-06-15       Impact factor: 5.156

Review 5.  Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe.

Authors:  Claire S Martin; Mark S Cooper; Rowan S Hardy
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

6.  In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice.

Authors:  Qin Shi; Elsa-Patricia Rondon-Cavanzo; Isadora Pfeifer Dalla Picola; Marcio José Tiera; Xiaoling Zhang; Kerong Dai; Houda Abir Benabdoune; Mohamed Benderdour; Julio Cesar Fernandes
Journal:  Int J Nanomedicine       Date:  2018-01-12

7.  Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.

Authors:  Konstantinos Anargyrou; Despina Fotiou; Theodoros P Vassilakopoulos; Dimitrios Christoulas; Polyzois Makras; Maria Dimou; Ioannis Ntanasis-Stathopoulos; Stavroula Masouridou; Maria K Angelopoulou; Athanasios Papatheodorou; Konstantinos Tsionos; Panayiotis Panayiotidis; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Hemasphere       Date:  2019-09-24

8.  Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial.

Authors:  Pradeesh Sivapalan; Niklas R Jørgensen; Alexander G Mathioudakis; Josefin Eklöf; Therese Lapperre; Charlotte Suppli Ulrik; Helle F Andreassen; Karin Armbruster; Praleene Sivapalan; Julie Janner; Nina Godtfredsen; Ulla M Weinreich; Thyge L Nielsen; Niels Seersholm; Torgny Wilcke; Philipp Schuetz; Tobias W Klausen; Kristoffer Marså; Jørgen Vestbo; Jens-Ulrik Jensen
Journal:  Respir Res       Date:  2020-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.